Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

9
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
9
Nephrons01:10

Nephrons

2.7K
The kidneys are intricate organs with millions of working units known as nephrons. Each nephron features two major structures: the renal corpuscle, which facilitates blood plasma filtration, and the renal tubule, which handles the glomerular filtrate. Blood supply is directly linked to the nephrons. The renal corpuscle consists of the glomerulus, a capillary network, and the Bowman's capsule, a double-walled epithelial structure that encases the glomerulus. The filtering of blood plasma...
2.7K
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

26
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
26
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

28
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
28
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

29
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
29
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

42
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
42

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Corrigendum to "International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology." Kidney International, 2023;104:36-45.

Kidney international·2023
Same author

Serum phosphate is associated with increased risk of bone fragility fractures in haemodialysis patients.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2023
Same author

Use of Analog and Human Insulin in a European Hemodialysis Cohort With Type 2 Diabetes: Associations With Mortality, Hospitalization, MACE, and Hypoglycemia.

American journal of kidney diseases : the official journal of the National Kidney Foundation·2023
Same author

Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.

Lancet (London, England)·2023
Same author

Sodium-glucose cotransporter 2 inhibition in primary and secondary glomerulonephritis.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2023
Same author

Novel agents for treating IgA nephropathy.

Current opinion in nephrology and hypertension·2023
Same journal

Innere Medizin (Heidelberg, Germany)·2026
Same journal

Innere Medizin (Heidelberg, Germany)·2026
Same journal

Innere Medizin (Heidelberg, Germany)·2026
Same journal

[Optimal blood pressure control in patients with diabetes and arterial hypertension: interpreting the BPROAD study].

Innere Medizin (Heidelberg, Germany)·2026
Same journal

[Distributive justice in healthcare during times of change: a medical ethics perspective].

Innere Medizin (Heidelberg, Germany)·2026
Same journal

[Update on the pharmacotherapy of chronic heart failure with reduced ejection fraction: from four to six pillars?]

Innere Medizin (Heidelberg, Germany)·2026
查看所有相关文章

相关实验视频

Updated: Jul 17, 2025

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.9K

[IgA脏病] 这是一个很好的方法.

Jürgen Floege1

  • 1Medizinische Klinik II, Uniklinik der RWTH Aachen, Pauwelsstr. 30, 52074, Aachen, Deutschland. jfloege@ukaachen.de.

Innere Medizin (Heidelberg, Germany)
|September 6, 2023
PubMed
概括
此摘要是机器生成的。

IgA脏病 (IgAN) 是一种常见的脏疾病,通常是晚诊断的. 尼菲康为高风险患者提供了一种新的向治疗,其他疗法正在开发中.

关键词:
补充 补充 补充 补充淋巴细胞炎 (Glomerulonephritis) 是一个葡萄糖皮质类药物是什么蛋白质尿症是一种蛋白质尿症.雷宁 - ангиотензин 系统

更多相关视频

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

23.7K
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.8K

相关实验视频

Last Updated: Jul 17, 2025

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
05:39

Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice

Published on: July 8, 2020

1.9K
5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

23.7K
Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy
14:18

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

1.8K

科学领域:

  • 腎臟病學 (nephrology) 是一種醫學專業.
  • 免疫学 免疫学 免疫学

背景情况:

  • IgA脏病 (IgAN) 是最常见的原发性淋巴结核炎,其特征是IgA1沉积在淋巴结核中.
  • 疾病的发病因子尚未完全理解,涉及异常的IgA1循环和沉积导致炎症.
  • 伊格纳通常呈现无症状,诊断通常发生在功能受损时脏活检时.

研究的目的:

  • 审查目前对IgA病变 (IgAN) 病原和临床表现的理解.
  • 讨论IGAN的预后指标和当前治疗策略.
  • 突出新疗法发展,包括Nefecon和正在进行的临床试验.

主要方法:

  • 关于IgA脏病 (IgAN) 病原,临床过程和治疗的文献综述.
  • 分析预后因素,如蛋白尿和损伤.
  • 评估现有和新兴的治疗方案,包括皮质类固醇和Nefecon.

主要成果:

  • IgAN 诊断通常是延迟的,蛋白尿和损伤是预后的关键指标.
  • 由于副作用,欧洲IgAN患者的全身皮质类固醇疗效受到争议.
  • 尼菲康 (封装布迪索尼德) 是首个批准用于高风险Igan患者的向治疗.

结论:

  • 需要更好地了解IgA病 (IgAN) 的起源和早期诊断.
  • 治疗策略正在不断发展,Nefecon代表了高风险个体的重大进步.
  • 目前正在进行的临床试验正在探索新的方法,以有效地管理Igan.